CD44 and hepatocellular carcinoma: The reduced drug effectiveness in rhPRG4-exposed CD44-silenced cells is consistent with the lesser sensitivity to rhPRG4 of drug-exposed low CD44-expressing HCC cell lines PLC/PRF/5 and Hep3B (see Fig. 5).